News

Why Novo Nordisk Stock Imploded This Week

Shares of Novo Nordisk ( NVO 2.48%) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...

Novo Nordisk Cut Its Outlook and Named a New CEO. Its Stock Is Plummeting

U.S.-listed shares of Novo Nordisk (NVO) sank roughly 20% in premarket trading after the Danish drugmaker cut its full-year ...

Novo Nordisk: Is This An Overreaction Or The End Of The GLP-1 Fairy Tale?

Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...

Novo Nordisk stock posts worst week since 2021, but analysts see a bigger problem ahead

Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.

A Medicare experiment could change who gets Ozempic

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

Novo Nordisk's Downgraded Expectations - What The Market Is (Obviously) Missing

Novo Nordisk A/S shares plunged after a Q2 revenue update and 2025 guidance downgrade. Click here to find out why NVO stock ...

Medicare and Medicaid move toward covering Ozempic and other weight loss drugs

Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...

How Novo Nordisk Gave Up Its Weight-Loss Gains

For a while, Danish drugmaker Novo Nordisk A/S looked unstoppable. It was at the forefront of the weight-loss injection boom as people discovered that its Ozempic shot, originally developed to treat ...